Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Ivan Zanoni · BOSTON CHILDREN'S HOSPITAL · 2022 · $751,928 — PROJECT SUMMARY Vaccines represent a highly effective public health measure to protect individuals from infectious diseases. Many vaccines work by inducing antigen-specific antibodies that neutralize the pathogen or its products and promote their clearance. Vaccines based on protein antigens usually…
RONALD N HARTY · FOX CHASE CHEMICAL DIVERSITY CENTER, INC · 2022 · $306,500 — The ultimate goal of this Phase I application is to discover and develop host-oriented small molecule compounds targeting Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection. SARS-CoV-2 is a novel coronavirus driving the current global pandemic of severe respiratory syndrome in hu…
Samarjit Das · JOHNS HOPKINS UNIVERSITY · 2022 · $500,000 — Abstract This supplement is in response to Funding Opportunity Announcement Number PA-20-272 Administrative Supplements to Existing NIH Grants and Cooperative Agreements. The supplement application is in response to the RADx-rad announcement on the opportunity of additional resources and funding sup…
David Margulies · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2022 · $51,958 — We have successfully engineered and produced a number of SARS-CoV-2 proteins, subunits, and single domain antibodies directed against the RBD. These purified proteins have provided the materials for obtaining high resolution crystal structures of four of these sybodies in complex with the Spike rece…
Mitchell Ho · DIVISION OF BASIC SCIENCES - NCI · 2022 · $45,270 — During the pandemic, Dr Ho has evaluated the challenges for developing antibody therapeutics targeting SARS-Cov-2 and wrote a review/perspective article [Ho Antibody Therapeutics 2020; PMID: 32566896]. SARS-CoV-2 gains entry to human cells through its spike (S) protein binding to angi…
Joseph Rodriguez · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · 2022 · $300,295 — Viruses use host components for their entire life cycle, from transcription and RNA processing of viral components to export and reinfection of new cells. ACE2 is an estrogen responsive cell receptor used by COVID19 to dock and enter host cells. TMPRSS2 is also an estrogen and androgen responsive …
ROBERT A SEDER · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2022 · $332,304 — NHP immunized with 10 and 100g of mRNA-1273 encoding the SARS CoV2 had robust neutralizing antibodiy titers following two immunizations. mRNA-1273 induced Th1-biased CD4 T cell responses and low or undetectable Th2 or CD8 T responses. Following an infectious challenge with SARS CoV2 by the intrana…
Anirban Banerjee · EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT · 2022 · $12,607,429 — 1) Structure and function of eukaryotic integral membrane enzymes that catalyze protein lipidation - A. Structural and chemical biology of zDHHC palmitoylacyltransferases - Of the different forms of protein lipidation, protein S-acylation, commonly known as protein palmitoylation, is the most prev…
Dima A Hammoud · CLINICAL CENTER · 2022 — Progress: Sars-Cov-2 project: We have started our experiments by developing the LPS lung injury model by administering LPS intratracheally. We are using male and female mice, including WT and ACE2 Transgenic mice. At this stage we are imaging the lung infiltrates and assessing ACE2 levels in the var…
Aleksandra Nita-Lazar · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2022 · $1,155 — The focus of the proteomic approach is to identify and quantify viral structural proteins, specifically spike (S) glycoprotein as well as envelope (E) protein, membrane (M) protein, and nucleocapsid (N) protein in patient samples. The S protein mediates attachment of the virus to the host cell surfa…
Ursula Buchholz · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2022 · $321,289 — We are developing paramyxovirus vectored vaccines for intranasal immunization against SARS-CoV-2. The vaccine vectors express prefusion-stabilized versions of the SARS-CoV-2 S protein and are designed to be highly attenuated in humans while maintaining a high level of immunogenicity at the primary s…
Dax A Hoffman · EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT · 2022 · $2,257,955 — Isomerase regulation of potassium channel trafficking and function. We recently identified a novel molecular cascade initiated by the activation of p38 kinase and subsequent Pin1dependent isomerization of a C-terminal motif (T607) in Kv4.2 that triggers dissociation from its auxiliary subunit DPP6,…
JOHN H KEHRL · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2022 · $40,147 — Beta-Coronaviruses are a family of positive-strand enveloped RNA viruses that includes the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Our recent studies have focused on two SARS-CoV-2 encoded proteins, open reading frame (ORF) 3a and 8. Previous studies of SARS-CoV-1 identified O…
paolo lusso · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2022 · $160,169 — Following the success of our HIV vaccine platform based on co-formulated Env+Gag mRNA in order to produce non-infectious VLPs (Zhang et al., Nat. Med. 27:2234, 2021), in collaboration with Moderna, Inc., we have designed a similar vaccine platform for SARS-CoV-2. The major results obtained include t…
Mark Connors · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2022 · $217,764 — Our laboratory is engaged in the study of the immune response to SARS-CoV-2 in two major areas. The first of these is the study of the immune response to natural infection. The second is the response to virus-like particles or replicating recombinant adenovirus type 4 (Ad4) vaccines. We are colla…
Pamela Frischmeyer-Guerrerio · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2022 · $612,630 — The SARS-CoV-2 virus has incited a global pandemic leading to profound loss of human life and tremendous economic and social upheaval. The FDA has now approved two mRNA vaccines produced by Pfizer-BioNTech and Moderna that were found to be highly effective in Phase 3 trials at preventing COVID-19. T…
Robert Petrovich · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · 2022 · $1,352,350 — The protein expression facility (PEF) functions as a support group for the principal investigators at the NIEHS. Our focus is to provide the research groups with a means to generate the proteins they require so that they can perform their experiments. These projects range from generating enough o…
Lesia Dropulic · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2022 · $680,544 — This project includes the evaluation of a vaccine candidate targeting SARS-CoV-2, mRNA-1273, that was administered to healthy volunteers in a phase 1 trial (DMID 20-0003). This project also includes the collection of samples for translational immunology research from participants who have been vacci…
Thomas Redmond · NATIONAL EYE INSTITUTE · 2022 · $367,569 — Novel coronavirus SARS-CoV-2, originating at the end of 2019 in Wuhan, China, causes the pandemic coronavirus disease COVID-19 that has had a major public health and economic impact in the USA and the rest of the world since then. The disease is quite heterogeneous and targets internal organs with m…
Alan Koretsky · NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE · 2022 · $1,663,773 — We have made substantial progress towards Aims 1-5, 7&8. Specifically: a) We have reproducibly fabricated 3 nm iron oxide nanoparticles independently in our own lab. These serve as good T1 MRI contrast agents and have strong T2 contrast properties as well. b) We have developed several camelid VHH a…